Contributions
Abstract: EP1586
Type: Poster Sessions
Abstract Category: Therapy - Immunomodulation/Immunosuppression
Introduction: Unacceptable tolerability may be the reason for considering treatment switch from platform madications to oral agents in multiple sclerosis (MS). Both fingolimod and teriflunomide can be used effectively. used in multiple sclerosis (MS). Early relapse outcomes in long-term stable patients switching from IFNb and GA to oral madications have been stimulating issues.
Aims: To compare relapse possibilities and cognitive and magnetic resonance imaging (MRI) issues in patients switching injectables to fingolimod or teriflunomide.
Methods: RRMS patients who were stable at least one year with paltform injectables were recruited. Annual relapse rate, disability progression, number of new T2 lesions and new T1 lesions (black holes), and symbol digit modalities test scores were compared in switchers (previously stable MS patients switching from platform injectables) and stayers (patients remaining on IFNβ/GA).
Results: A total of 406 switchers were matched to 324 stayers. There was no difference in the proportion of patients recording at least one relapse in the first year (3.4% switchers, 2.9% stayers; P = 0.085). The mean annualized relapse rate (P = 0.19) and EDSS progression (0.09) were also comparable. There was no significant difference between two groups on the basis of new T2 lesion (p=0.14) and new T1 lesion (p=0.754). İnformation prossessing speed measured by SDMT was also did not change in this period for both groups (p=0.08)
Conlusions: Our results indicated that there was no evidence of disease reactivation in terms of relase possibility, MRI activitiy and cognitive status within the first year in patients switching to oral therapy when they were previously stable, and both fingolimod and teriflunomide had similar results in this respect.
Disclosure: Serkan Ozakbas: nothing to disclose
Bilge Piri Cinar: nothing to disclose
Cavid Babayev: nothing to disclose
Abstract: EP1586
Type: Poster Sessions
Abstract Category: Therapy - Immunomodulation/Immunosuppression
Introduction: Unacceptable tolerability may be the reason for considering treatment switch from platform madications to oral agents in multiple sclerosis (MS). Both fingolimod and teriflunomide can be used effectively. used in multiple sclerosis (MS). Early relapse outcomes in long-term stable patients switching from IFNb and GA to oral madications have been stimulating issues.
Aims: To compare relapse possibilities and cognitive and magnetic resonance imaging (MRI) issues in patients switching injectables to fingolimod or teriflunomide.
Methods: RRMS patients who were stable at least one year with paltform injectables were recruited. Annual relapse rate, disability progression, number of new T2 lesions and new T1 lesions (black holes), and symbol digit modalities test scores were compared in switchers (previously stable MS patients switching from platform injectables) and stayers (patients remaining on IFNβ/GA).
Results: A total of 406 switchers were matched to 324 stayers. There was no difference in the proportion of patients recording at least one relapse in the first year (3.4% switchers, 2.9% stayers; P = 0.085). The mean annualized relapse rate (P = 0.19) and EDSS progression (0.09) were also comparable. There was no significant difference between two groups on the basis of new T2 lesion (p=0.14) and new T1 lesion (p=0.754). İnformation prossessing speed measured by SDMT was also did not change in this period for both groups (p=0.08)
Conlusions: Our results indicated that there was no evidence of disease reactivation in terms of relase possibility, MRI activitiy and cognitive status within the first year in patients switching to oral therapy when they were previously stable, and both fingolimod and teriflunomide had similar results in this respect.
Disclosure: Serkan Ozakbas: nothing to disclose
Bilge Piri Cinar: nothing to disclose
Cavid Babayev: nothing to disclose